Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 413 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: naltrexone Clear all
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Results available

ED Initiated Oral Naltrexone for AUD

NCT04817410
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Emergency Department Initiated Oral Naltrexone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

NCT02317744
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Naltrexone and bupropion combination, Pill Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

NCT05037032
View directory record Official record
Conditions
Altitude, Sleep Apnea, Central
Interventions
Naltrexone Pill, Placebo
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

NCT01873729
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

NCT00476242
View directory record Official record
Conditions
Opioid Dependence, Heroin Dependence
Interventions
Vivitrol, memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 4 Interventional

Sertraline for Alcohol Dependence and Depression

NCT00004554
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
naltrexone (Revia), sertraline (Zoloft), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 2, 2026, 2:00 PM EDT
Not listed Phase 2 Interventional

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

NCT06434818
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
Interventions
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 2, 2026, 2:00 PM EDT
Withdrawn Phase 2 Interventional

Neurobiology of Opioid Dependence: 4 - 4

NCT00000195
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1998
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

Fostering MAT Use in Justice Populations

NCT04363320
View directory record Official record
Conditions
Opioid-use Disorder, Recidivism
Interventions
NIATx Coaching, ECHO
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 2, 2026, 2:00 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Oral Naltrexone In Pediatric Eating Disorders

NCT05073679
View directory record Official record
Conditions
Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical, Anorexia Nervosa, Binge Eating/Purging Type, Purging (Eating Disorders), Impulsive Behavior, Eating Disorders, Bulimia Nervosa, Eating Disorders in Adolescence
Interventions
Naltrexone Hydrochloride, Control
Drug · Other
Lead sponsor
Rosemary Claire Roden
Other
Eligibility
13 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

NCT01721070
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).

NCT01750060
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Fentanyl, Naltrexone
Drug
Lead sponsor
Incline Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 4 Interventional

Naltrexone Treatment for Alcoholic Women

NCT00000448
View directory record Official record
Conditions
Alcoholism, Eating Disorder
Interventions
naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 2, 2026, 2:00 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Opioids and Social Support Enhanced Extinction Effects

NCT04166071
View directory record Official record
Conditions
Fear
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 2, 2026, 2:00 PM EDT
Withdrawn Not applicable Interventional

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

NCT00675532
View directory record Official record
Conditions
Drug Dependence
Interventions
Primary Care Counseling, Cognitive-behavioral psychotherapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 3 Interventional

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

NCT00167232
View directory record Official record
Conditions
Cocaine Dependence, Alcoholism
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Effects of Naltrexone on Nicotine Reinforcement

NCT00270231
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 2, 2026, 2:00 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 2, 2026, 2:00 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

NCT01673594
View directory record Official record
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 2, 2026, 2:00 PM EDT